| Excerpt | Reference |
|---|
| "We utilized three established HNSCC cell lines, SCC1, SCC6 and SCC1483 and measured nuclear translocation of EGFR after treatment with cetuximab or radiation." | ( Dunn, EF; Iida, M; Li, C; Wheeler, DL, 2010) |
| "Patients with biopsy-proven head and neck squamous cell carcinoma (HNSCC) treated with radical radiotherapy and weekly concurrent cisplatin 40 mg/m(2) at the South Egypt Cancer Institute (Assiut) were randomly assigned to one of the following groups: treatment group (prophylactic trolamine emulsion every 8 h, 4 h apart from the radiotherapy session) or control group (usual supportive care)." | ( Abbas, H; Bensadoun, RJ, 2012) |
| "A tissue microarray composed of 102 HNSCC treated with (chemo)radiation was constructed and analyzed for EGFR copy number by FISH (Vysis; Abbott Laboratories) and EGFR protein expression using AQUA analysis of EGFR staining scored on a scale of 0 to 255." | ( Burtness, B; Fountzilas, G; Kountourakis, P; Kowalski, D; Pectasides, E; Psyrri, A; Rampias, T; Rimm, D; Sasaki, C; Zaramboukas, T, 2011) |
| "Head and neck squamous cell carcinoma (HNSCC) is usually fatal, and innovative approaches targeting growth pathways are necessary to effectively treat this disease." | ( Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H, 2011) |
| "Patients with recurrent HNSCC or a second primary not amenable to curative-intent treatment were randomized to the R-RT arm (concurrent re-irradiation, fluorouracil and hydroxyurea) or to the Ch-T arm (methotrexate)." | ( Bardet, E; Benhamou, E; Bontemps, P; Bourhis, J; Calais, G; Daly-Schveitzer, N; Janot, F; Lapeyre, M; Lesaunier, F; Lusinchi, A; Maingon, P; Tao, Y; Tortochaux, J; Tournay, E; Verrelle, P, 2011) |
| "The results show that lymphocytes from HNSCC patients and HTB-43 or SSC-25 cancer cells were more sensitive to genotoxic treatment with UV-radiation and displayed impaired DNA repair." | ( Blaszczyk, J; Dziki, L; Kabzinski, J; Majsterek, I; Markiewicz, L; Milonski, J; Olszewski, J; Rusin, P; Sliwinski, T; Szemraj, J, 2011) |
| "Mechanisms of resistance for HNSCC to cisplatin (CDDP), the foundational chemotherapeutic agent in the treatment of this disease, remain poorly understood." | ( Jiffar, T; Kupferman, ME; Lee, J, 2012) |
| "The mainstay of the treatment of head and neck squamous cell carcinoma (HNSCC) is radiotherapy, which acts by producing free radicals." | ( Arora, K; Dahiya, K; Dhankhar, R; Madaan, H; Singh, V, 2012) |
| "Mice bearing established HNSCC xenografts were treated with PD173074 (12 mg/kg), and tumor histology was analyzed for stromal composition, proliferation (Ki67 staining), and apoptosis (TUNEL [terminal deoxynucleotidyl transferase dUTP nick end labeling] staining)." | ( Hart, J; Hartman, YE; Lancaster, W; Liu, Z; Rosenthal, EL; Sweeny, L, 2012) |
| "Induction chemotherapy in head and neck squamous cell carcinoma does not compromise delivery of definitive radiotherapy with or without concurrent chemotherapy." | ( Geropantas, K; Loo, SW; Martin, C; Roques, TW; Tasigiannopoulos, Z, 2013) |
| "pSTAT3 expression was assessed in human HNSCC tumors that recurred following cetuximab treatment." | ( Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L, 2012) |
| "Biopsies from HNSCC tumors that recurred following cetuximab treatment showed increased STAT3 activation compared with pretreatment biopsies." | ( Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L, 2012) |
| "Treatment of HNSCC cells with apricoxib also causes greater upregulation of E-cadherin and Muc1 expression and downregulation of vimentin, as compared with celecoxib treatment." | ( Burrows, FJ; Dennis, M; Dohadwala, M; Dubinett, SM; Elashoff, D; Hu, D; Lawhon, T; Lee, JM; Lin, Y; Luo, J; St John, MA; Wang, G; Zaknoen, SL, 2012) |
| "Despite the high expression of EGFR in HNSCC, EGFR inhibitors have only limited success as monotherapy." | ( Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D, 2013) |
| "Patients with stage III/IV HNSCC, in whom DCF induction chemotherapy followed by concurrent chemoradiotherapy had been validated by a multidisciplinary team, were prospectively included in the study." | ( Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G, 2012) |
| "Constitutive activation of the AhR in HNSCCs was blocked by antagonist treatment, leading to a reduction in IL6 expression." | ( Amin, SG; DiNatale, BC; John, K; Krishnegowda, G; Perdew, GH; Smith, K, 2012) |
| "Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m² on days 1 and 5-Fu 750 mg/m² on days 1-5 q3wks)." | ( Guo, Y; Hu, CS; Ji, QH; Wang, Y; Zhao, XY; Zhu, GP; Zhu, YX, 2012) |
| "For resectable HNSCC, nimotuzumab plus PF regimen as induction treatment is highly effective for preserving the organ function and the toxicities are well tolerable." | ( Guo, Y; Hu, CS; Ji, QH; Wang, Y; Zhao, XY; Zhu, GP; Zhu, YX, 2012) |
| "Patients with squamous cell carcinoma of the head and neck were treated with ACPF (nab-paclitaxel 100 mg/m(2) /week; cetuximab 250 mg/m(2) /week; cisplatin 75 mg/m(2) on day 1; 5-FU 750 mg/m(2) /day on days 1 through 3) every 21 days for 3 cycles followed by CRT (cisplatin 100 mg/m(2) on days 1, 22, and 43 of radiation therapy [RT])." | ( Adkins, D; Dehdashti, F; Gay, H; Lewis, J; Ley, J; Mehan, P; Nussenbaum, B; Siegel, BA; Thorstad, W; Trinkaus, K; Wildes, T, 2013) |
| "Treatment of human HNSCC cell lines from different sub-sites, such as oral cavity (SCC1), larynx (SCC5), tongue (OSC19) and pharynx (FaDu), with grape seed proanthocyanidins (GSPs) reduced their cell viability and induced cell death in a dose- and time-dependent manner." | ( Katiyar, SK; Prasad, R, 2012) |
| "In this study, HNSCC cell lines were treated with EGF, and CK expression levels were monitored by Western blot analysis." | ( Bakowsky, U; Bette, M; Betz, T; Cai, C; Jacob, R; Makarova, G; Mandic, R; Moll, R; Neff, A; Ocker, M; Rodepeter, F; Schmidt, A; Sesterhenn, A; Sitterberg, J; Teymoortash, A; Werner, JA, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) is characterized by overexpression of the epidermal growth factor receptor (EGFR) where treatments targeting EGFR have met with limited clinical success." | ( Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L, 2012) |
| "Head and neck squamous cell carcinoma (HNSCC) is a common malignancy that continues to be difficult to treat and cure." | ( Barnes, L; Cardesa, A; Devaney, KO; Ferlito, A; Gnepp, DR; Hunt, JL; Lewis, JS; Mahfouz, ME; Rinaldo, A; Rodrigo, JP; Slootweg, PJ; Takes, RP; Thompson, LD; Triantafyllou, A; Westra, WH; Woolgar, JA, 2014) |
| "Treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) uses a multidisciplinary approach often limited by the toxicity and drug resistance of platinum agents." | ( Cai, S; Cohen, MS; Cohen, SM; Durham, D; Forrest, ML; Mukerji, R; Rockefeller, N; Shnayder, Y, 2013) |
| "Injection with MDA-1986 HNSCC cells followed by 3 weeks of treatment with cisplatin, HA-cisplatin, phosphate-buffered saline, or HA only." | ( Cai, S; Cohen, MS; Cohen, SM; Durham, D; Forrest, ML; Mukerji, R; Rockefeller, N; Shnayder, Y, 2013) |
| "Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations." | ( Anderson, RT; Arcaroli, JJ; Astling, DP; Bowles, DW; Eagles-Soukup, JR; Glogowska, MJ; Goddard, JA; Hausman, DF; Helber, RM; Hirsch, FR; Jimeno, A; Kako, SL; Keysar, SB; Le, PN; Leem, TH; Macfadden, SM; Messersmith, WA; Morton, JJ; Paylor, JJ; Peterson, S; Pittman, MA; Raben, D; Robinson, WA; Said, S; Sehrt, DB; Song, JI; Takimoto, SM; Tan, AC; Umpierrez, A; Varella-Garcia, M; Vogler, BW; Wang, XJ, 2013) |
| "The effect of autophagy on HNSCC viability after nanoparticle-induced photocatalytic treatment seems to depend on the impact of the physicochemical trigger." | ( Burghartz, M; Froelich, K; Ginzkey, C; Gohla, A; Hackenberg, S; Hagen, R; Kleinsasser, N; Koehler, C; Scherzed, A; Technau, A, 2014) |
| "All patients with N3 (>6 cm) HNSCC treated with definitive chemoradiotherapy (CRT) at our institution between 2005 and 2012 were included in the analysis." | ( Adams, G; Burmeister, B; Foote, M; Panizza, B; Porceddu, SV; Pryor, DI; Rowan, A, 2014) |
| "Most head and neck squamous cell carcinomas (HNSCCs) overexpress epidermal growth factor receptor (EGFR) and EGFR inhibitors are routinely used in the treatment of HNSCC." | ( Case, AJ; Domann, FE; Fletcher, EV; Love-Homan, L; Miller, FJ; Raeburn, A; Schickling, BM; Simons, AL; Sobhakumari, A, 2013) |
| "Patients with HNSCC treated between January 2005 and December 2010 with radical intent with either TPF or cisplatin and 5-FU (PF) ICT and documented intention to proceed with concurrent cisplatin CRT were identified retrospectively." | ( Coyle, C; Dyker, KE; Karakaya, E; Prestwich, RJ; Sen, M; Teo, M; Young, CA, 2013) |
| "For the head and neck squamous cell carcinoma (HNSCC), surgery in combination with radiation therapy is the current standard treatment." | ( Chen, LW; Chen, TC; Chiang, KC; Flanagan, JN; Hsu, JT; Huang, CC; Juang, HH; Kittaka, A; Kuo, SF; Pang, JH; Sun, CC; Takano, M; Yang, SW; Yeh, CN, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat, and despite of advances in treatment, the overall survival rate has only modestly improved over the past several years." | ( Crawford, S; Gonzalez, JG; Nerurkar, P; Rajamoorthi, A; Ray, RB; Shrivastava, S; Steele, R; Varvares, M, 2013) |
| "Early detection of recurrence of head and neck squamous cell carcinoma (HNSCC), which is often obscured by surgical or radiotherapy-induced tissue distortion, is essential for proper patient management." | ( Cho, KJ; Choi, SH; Kim, JS; Kim, JW; Kim, SY; Lee, JH; Nam, SY; Roh, JL, 2013) |
| "Human head and neck squamous cell carcinoma (HNSCC) fundamentally vary in their susceptibility to different cytotoxic drugs and treatment modalities." | ( Bechmann, I; Dietz, A; Gerlach, MM; Kubick, C; Lordick, F; Merz, F; Wichmann, G; Wittekind, C, 2014) |
| "Phase II trials in HNSCC show that daily oral treatment with afatinib is tolerable." | ( Ferrarotto, R; Gold, KA, 2014) |
| "A retrospective study of patients with head and neck squamous cell carcinoma (HNSCC), treated in Denmark between 1990 and 2013." | ( Frederiksen, KD; Metwally, MA; Overgaard, J, 2014) |
| "167 consecutive patients with HNSCC who received concurrent chemo-radiotherapy at the Basel University Hospital between 1988 and 2006 were analyzed retrospectively with a special focus on early deaths and risk factors for an unfavorable outcome." | ( Buess, M; Fischer, C; Naehrig, D; Rochlitz, C; Schlumpf, M, 2013) |
| "Patients with R/M HNSCC previously treated with chemotherapy were eligible." | ( Apollo, A; Cox, L; Fury, MG; Haque, S; Ho, AL; Lipson, BL; Lyo, JK; Pfister, DG; Sales, R; Seetharamu, N; Sherman, EJ; Sima, CS; Xiao, H, 2014) |
| "The synchronized oral squamous cell carcinoma cell lines (Cal27, GNM, and WSU-HN6) were treated with different concentrations of NaHS and then subjected to cell proliferation, cell cycle, and Western blot analyses." | ( Bi, Q; Ma, Z; Wang, Y, 2015) |
| "Three HNSCC cell lines (FaDu, Detroit562 and BICR6) were treated with cisplatin or radiation." | ( Doki, Y; Fukusumi, T; Hamabe, A; Haraguchi, N; Hasegawa, S; Inohara, H; Ishii, H; Kano, Y; Konno, M; Mori, M; Nakahara, S; Nishikawa, S; Ogawa, H; Takenaka, Y; Yamamoto, Y; Yasui, T, 2014) |
| "The study included 214 biopsy-proven HNSCC patients who underwent a posttherapy PET/CT study, between 5 and 24 wk after completion of treatment." | ( Ciarallo, A; Kang, H; Kiess, AP; Koch, W; Marcus, C; Mena, E; Subramaniam, RM; Tahari, AK; Wahl, RL, 2014) |
| "Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial." | ( Chen, CH; Lin, SF; Liu, YC; Sun, Y; Tang, JY; Wu, CF; Yang, WC, 2014) |
| "520 patients received radiotherapy for HNSCC from 2005 to 2009." | ( Aznar, MC; Bentzen, SM; Berthelsen, AK; Due, AK; Korreman, SS; Kristensen, CA; Loft, A; Specht, L; Vogelius, IR, 2014) |
| "In locally advanced head and neck squamous cell carcinoma, carboplatin and cisplatin have both been found to produce a survival benefit when added to radiation therapy." | ( Adelstein, DJ; Nwizu, T, 2014) |
| "From 01/2006 to 08/2012, 173 LAHNSCC patients treated as a curative intent by T-ICT, followed by definitive RT/CRT were included in this analysis." | ( Bellefqih, S; Blanchard, P; Bourhis, J; Brahimi, N; Daly-Schveitzer, N; Guigay, J; Janot, F; Levy, A; Tao, Y; Temam, S, 2014) |
| "In patients with recurrent/distant HNSCC, one of the limited treatment options is etoposide." | ( Bigenzahn, J; Brunner, M; Heiduschka, G; Thurnher, D, 2014) |
| "As the overall survival rates of squamous cell carcinoma of the head and neck (HNSCC) remain poor due to limitations in surgery and irradiation and chemotherapy resistance, SphK1 is an important enzyme to investigate." | ( Brockhoff, G; Doescher, J; Haug, A; Mißlbeck, M; Pickhard, A; Piontek, G; Reiter, R; Rudelius, M; Schiefler, C; Schuettler, D, 2014) |
| "Patients with previously untreated HNSCC received vandetanib daily for 14 days (starting dose 100 mg) and then vandetanib + RT (2." | ( Chen, CR; Cohen, EW; Frank, SJ; Heymach, JV; Hirsch, FR; Jimeno, A; Lin, H; Lowe, ES; Myers, JN; Nedzi, L; Papadimitrakopoulou, VA; Raben, D; Tran, HT; Vasselli, JR, 2016) |
| "Thirty-eight patients with advanced HNSCC underwent 11C-4DST PET/CT and 18F-FDG PET/CT before treatment." | ( Ishiwata, K; Ito, K; Kubota, K; Minamimoto, R; Miyata, Y; Morooka, M; Okasaki, M; Toyohara, J; Yokoyama, J, 2015) |
| "A panel of HNSCC cell lines with varying genetic alterations in cell death pathway components were treated with birinapant ± TNFα, TRAIL, and docetaxel and were assessed for effects on cell density, cell cycle, and death." | ( Carlson, SG; Chen, Z; Eytan, DF; Schiltz, S; Snow, GE; Van Waes, C, 2015) |
| "The treatment of head and neck squamous cell carcinoma (HNSCC) with N3 (>6cm) lymph nodes remains difficult, and the best treatment strategy has not been elucidated." | ( Hanai, N; Hasegawa, Y; Hirakawa, H; Nakashima, T; Nishikawa, D; Ozawa, T; Suzuki, H, 2015) |
| "Sixty-nine patients with HNSCC and N3 neck disease treated with definitive therapy in our institute between 1987 and 2013 were included in the analysis." | ( Hanai, N; Hasegawa, Y; Hirakawa, H; Nakashima, T; Nishikawa, D; Ozawa, T; Suzuki, H, 2015) |
| "Patients with recurrent or metastatic HNSCC who had received at least one and no more than two prior systemic treatment regimens were randomized (1 : 1) to cetuximab with or without PX-866 (8 mg p." | ( Choi, M; Cline-Burkhardt, V; Cohen, RB; Hausman, D; Jimeno, A; Kochenderfer, M; Laskin, J; Shirai, K; Spira, A; Walker, L; Winquist, E, 2015) |
| "In Stage III/IV head and neck squamous cell carcinoma of the head and neck, multidisciplinary treatment is not standardized." | ( Cassir, J; Davis, MA; Fanelle, J; Nazha, NT; Sachdeva, K; Slotman, GJ; Smith, G; Sudhindra, R; Tyrrell, J; Wurzer, JV, 2015) |
| "Twelve patients with locally advanced HNSCC underwent three FAZA PET-CT before treatment, after 7 fractions and after 17 fractions of a carboplatin-5FU chemo-radiotherapy regimen (70 Gy in 2 Gy per fraction over 7 weeks)." | ( Bol, A; Differding, S; Grégoire, V; Hanin, FX; Labar, D; Lee, JA; Servagi-Vernat, S; Sterpin, E, 2015) |
| "Tumor-specific immunity in response to HNSCC tumor lysate was augmented in tadalafil-treated patients (P = 0." | ( Agrawal, N; Blanco, R; Borrello, I; Califano, JA; Fakhry, C; Goodman, S; Gourin, CG; Ha, PK; Khan, Z; Koch, WM; Levine, M; Marur, S; Neuner, G; Noonan, KA; Richmon, JD; Rudraraju, L; Saunders, J; Serafini, P; Tang, M; Wang, H; Weed, DT; Zhang, Z, 2015) |
| "Three HNSCC cell lines (SCC25, CAL27 and FaDu) were treated with increasing doses of cafestol." | ( Brunner, M; Eckl-Dorna, J; Heiduschka, G; Kotowski, U; Kranebitter, V; Lill, C; Schmid, R; Seemann, R; Stanisz, I; Thurnher, D, 2015) |
| "Treatment of HNSCC cells with cafestol leads to a dose-dependent reduction of cell viability and to induction of apoptosis." | ( Brunner, M; Eckl-Dorna, J; Heiduschka, G; Kotowski, U; Kranebitter, V; Lill, C; Schmid, R; Seemann, R; Stanisz, I; Thurnher, D, 2015) |
| "Patients with locally advanced HNSCC were treated with APF-C (n = 30) or TPF-C (n = 38)." | ( Adkins, DR; Diaz, J; Gay, H; Lewis, J; Ley, J; Michel, L; Nussenbaum, B; Paniello, RC; Rich, J; Schell, A; Thorstad, W; Trinkaus, K; Wildes, TM; Wu, N, 2015) |
| "All had stage IV HNSCC, all achieved a complete response to treatment, and 9 of 10 remain alive, with a mean survival time of 61." | ( Gentry, LR; Harari, PM; Hartig, GK; Hoang, T; Jeraj, R; Khuntia, D; Kruser, TJ; McCulloch, TM; Nyflot, MJ; Traynor, AM; Wiederholt, PA; Yang, DT, 2015) |
| "The trial included HNSCCa patients treated with definitive RT." | ( Ang, KK; Cmelak, AJ; Hershock, D; Hong, S; Le, QT; Lin, A; Machtay, M; Nabid, A; Parliament, MB; Rotman, M; Shehata, S; Shenouda, G; Sultanem, K; Suntharalingam, M; Zhang, Q, 2015) |
| "AZD1480 treatment decreased HNSCC proliferation in HNSCC cell lines with half maximal effective concentration (EC50) values ranging from 0." | ( Black, J; Chiosea, SI; DeGrave, KA; Freilino, ML; Grandis, JR; Joyce, S; Lui, VW; Pollock, NI; Sen, M; Wheeler, S; Zeng, Y, 2015) |
| "However, only a subset of HNSCC patients benefit from anti-EGFR targeted therapy." | ( Bill, A; Bonenfant, D; Duvvuri, U; Gaither, LA; Gutierrez, A; Kemp, C; Kulkarni, S; Voshol, H, 2015) |
| "The treatment outcome of HNSCC at our centre is lagging behind those of developed nations." | ( Alip, A; Phua, VC; Wan Ishak, WZ; Wong, YF; Yusof, MM, 2015) |
| "In several head and neck squamous cell carcinoma (HNSCC) cell lines, we observed a pattern of oscillating decrease and increase of intracellular ATP level after cetuximab treatment, and the magnitude and kinetics of which varied by cell line and appeared to be linked to the extent of cellular response to cetuximab." | ( Fan, Z; Hong, Y; Li, X; Lu, H; Lu, Y; Luo, J, 2015) |
| "Activity of CCI-779 in HNSCC cells harboring TP53 mutations and displaying a phenotype of cisplatin resistance suggests its clinical potential even in patients with dismal outcome after current standard treatment." | ( Budach, V; Niehr, F; Stenzinger, A; Tinhofer, I; Weichert, W, 2015) |
| "HIV PIs sensitize HNSCC cells to radiotherapy by activation of ER stress and induction of cell cycle arrest." | ( Liu, R; Mikkelsen, R; Song, S; Yang, J; Zhang, L; Zhang, X; Zhou, H, 2015) |
| "Three cetuximab-sensitive HNSCC cell lines (SC263, LICR-HN2 and LICR-HN5) were treated with either cetuximab or erlotinib." | ( Baay, M; Boeckx, C; De Pauw, I; Lardon, F; Peeters, M; Van den Bossche, J; Wouters, A, 2015) |
| "Single patient with locally advanced HNSCC who received erlotinib monotherapy in a window-of-opportunity clinical trial (patients scheduled to undergo primary cancer surgery are treated briefly with an investigational agent)." | ( Bauman, JE; Carter, SL; Chiosea, S; Close, D; Du, Y; Duvvuri, U; Egloff, AM; Garraway, LA; Getz, G; Gilbert, BR; Goetz, EM; Golub, TR; Grandis, JR; Johnson, JT; Johnston, PA; Li, H; Lui, VW; McKenna, A; Mills, GB; Pendleton, KP; Sougnez, C; Stransky, N; Van Allen, EM; Wagle, N; Wang, L; Zeng, Y; Zhang, F, 2015) |
| "These patients with locally advanced HNSCC were treated with standard cisplatin-based chemoradiotherapy and received dose-escalating oral AT-101 in a 2-weeks daily schedule every 3 weeks." | ( Dubbelman, R; Hoebers, FJ; Kuipers, GK; Lafleur, MV; Slotman, BJ; Stoter, TR; van den Brekel, MW; Verheij, M; Zerp, SF, 2015) |
| "Treatment of unresectable HNSCC is not well defined and has a poor outcome." | ( Bhasker, S; Kumar, A; Mohanti, BK; Sharma, A; Shukla, NK; Sikka, K; Singh, CA; Thakar, A; Thulkar, SP; Vishnubhatla, S, 2015) |
| "Locally advanced and unresectable HNSCC patients (except Nasopharynx and Larynx) unfit for radical treatment were randomized to arm A [short course RT alone (4Gy/#/day for 5days)] or arm B [RT as arm A+concurrent cisplatin at 6mg/m(2)/day IV bolus for 5days]." | ( Bhasker, S; Kumar, A; Mohanti, BK; Sharma, A; Shukla, NK; Sikka, K; Singh, CA; Thakar, A; Thulkar, SP; Vishnubhatla, S, 2015) |
| "To identify changes in gene expression, HNSCC cell lines were treated with 10 μM paclitaxel for 48 h and analyzed by microarray analysis." | ( Maushagen, R; Pries, R; Wollenberg, B, 2015) |
| "The sensitivity of HNSCC cell lines to AZD4547, either as single or combination treatment with the EGFR inhibitor gefitinib, was assessed using long-term colony formation assays, short-term viability assays, and biochemical analysis." | ( Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM, 2016) |
| "We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC." | ( Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG, 2016) |
| "A total of 98 HNSCC patients were treated with primary surgical resection and had undergone PET/CT within 6 months of treatment completion." | ( Agrawal, N; Kang, H; Richmon, J; Sheikhbahaei, S; Subramaniam, RM; Taghipour, M; Wray, R, 2016) |
| "Although head and neck cancer (HNSCC) is the sixth most common tumor entity worldwide therapy options remain limited leading to 5-year survival rates of only 50 %." | ( Bootz, F; Brägelmann, J; Brossart, P; Deng, M; Duensing, S; Heasley, L; Kirfel, J; Kristiansen, G; Perner, S; Queisser, A; Sanders, C; Schröck, A; Thewes, B; Vogel, W; von Mässenhausen, A, 2016) |
| "In patients with R/M- Squamous cell carcinoma of the head and neck (SCCHN) who had progressed on/after first-line platinum-based therapy, afatinib induced significantly higher disease control rate, longer progression-free survival and improved patient-reported outcome compared to methotrexate." | ( Specenier, P; Vermorken, J, 2016) |
| "Head and neck cancers (thyroid and head and neck squamous cell carcinoma (HNSCC)) are relatively common malignancies and although often curable at initial diagnosis, treatment of advanced disease is palliative in intent." | ( Spector, M; Swiecicki, PL; Worden, FP, 2016) |
| "Importantly, AZD-2014's anti-HNSCC activity in vivo was potentiated with co-administration of ABT-737." | ( Cui, JT; Li, Y, 2016) |
| "Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy." | ( Bajrovic, A; Hakim, SG; Janssen, S; Kazic, N; Rades, D; Schild, SE; Seidl, D; Strojan, P; Wollenberg, B, 2016) |
| "JQ1 may be a new drug for oral squamous cell carcinoma treatment." | ( Huang, P; Lv, Z; Qi, Y; Wang, L; Wei, X; Wu, X; Yang, P; Zhang, F, 2016) |
| "Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up." | ( Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM, 2016) |
| "Locoregional recurrences of squamous cell carcinoma of the head and neck (SCCHN) are difficult to treat." | ( Hakim, SG; Rades, D; Schild, SE; Seidl, D; Wollenberg, B, 2016) |
| "Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage." | ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016) |
| "Head and neck squamous cell carcinoma (HNSCC) is a particularly challenging malignancy and requires more effective treatment strategies and a reduction in the debilitating morbidities associated with the therapies." | ( Katiyar, SK, 2016) |
| "A total of 891 patients with advanced HNSCC from a phase 3 trial of cisplatin plus radiotherapy with or without cetuximab (NRG Oncology RTOG 0522) were included in this study, and 413 patients with available samples were genotyped for the KRAS-variant." | ( Avizonis, VN; Axelrod, R; Chen, AM; Chin, R; Chung, CH; El-Naggar, AK; Ferris, RL; Galloway, TJ; Harris, J; Manon, RR; Matthiesen, C; Nguyen-Tan, PF; Raben, D; Schaue, D; Sidransky, D; Singh, AK; Skinner, H; Trotti, A; Wang, D; Weidhaas, JB; Yumen, O; Zhang, Q, 2017) |
| "Patients with the KRAS-variant with HNSCC significantly benefit from the addition of cetuximab to radiotherapy and cisplatin, and there is a significant interaction between the KRAS-variant and p16 status." | ( Avizonis, VN; Axelrod, R; Chen, AM; Chin, R; Chung, CH; El-Naggar, AK; Ferris, RL; Galloway, TJ; Harris, J; Manon, RR; Matthiesen, C; Nguyen-Tan, PF; Raben, D; Schaue, D; Sidransky, D; Singh, AK; Skinner, H; Trotti, A; Wang, D; Weidhaas, JB; Yumen, O; Zhang, Q, 2017) |
| "The invadopodia of HNSCC cells was markedly reduced after PFK15 treatment, thereby impairing cell motility and extracellular matrix degradation ability." | ( Chen, G; Jia, J; Li, HM; Liu, ZJ; Ren, JG; Wang, WM; Yang, JG; Yu, ZL; Zhang, W, 2017) |
| "Resminostat is a promising treatment of HNSCC because of its antiproliferative, chemosensitizing, and radiosensitizing effects." | ( Enzenhofer, E; Heiduschka, G; Kadletz, L; Kotowski, U; Schmid, R; Seemann, R; Stanisz, I; Thurnher, D, 2017) |
| "Cultured HNSCC cell lines were treated with inhibitors and subsequently irradiated." | ( Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W, 2017) |
| "The responsiveness of head and neck squamous cell carcinoma (HNSCC) to chemotherapy widely affects prognosis." | ( Chung, IJ; Joo, YE; Kim, SA; Lee, DH; Lee, JK; Lee, KH; Lim, SC; Park, YL; Yoon, TM, 2017) |
| "Despite advances in the head and neck squamous cell carcinoma (HNSCC) treatment modalities, drug resistance and cancer recurrence are often reported." | ( Alexandersson, L; Hansson, KT; Jönsson, JI; Roberg, K; Wiechec, E, 2017) |
| "Data regarding r/mHNSCC consecutive pts treated with cetuximab and platinum from 2009 to 2014 at our center were retrospectively collected." | ( Alfieri, S; Bergamini, C; Bossi, P; Cau, MC; Granata, R; Infante, G; Licitra, L; Locati, L; Miceli, R; Resteghini, C; Siano, M, 2017) |
| "Enhanced in vitro HNSCC cell death was observed with dasatinib-cetuximab versus single agent treatment; addition of IL6-containing media abrogated this effect." | ( Bauman, JE; Egloff, AM; Flaherty, JT; Geiger, JL; Gibson, MK; Gooding, WE; Grandis, JR; Ohr, J; Rothenberger, NJ; Stabile, LP; Wang, L; Zhou, P, 2017) |
| "The outcome of N3 HNSCC was extremely poor despite treatment intensification and no difference between CRT and VART." | ( Alfonsi, M; Aupérin, A; Bardet, E; Bourhis, J; Calais, G; Deprez, P; Geoffrois, L; Gery, B; Graff, P; Grégoire, V; Lapeyre, M; Maingon, P; Martin, L; Pignon, T; Rives, M; Sire, C; Tao, Y; Verrelle, P, 2017) |
| "Patients with HNSCC who underwent FDG-PET/CT after (chemo)radiotherapy were studied retrospectively." | ( Carp, L; Helsen, N; Roothans, D; Stroobants, S; Van Den Heuvel, B; Van den Weyngaert, D; Van den Wyngaert, T, 2017) |
| "Heterogeneity of HNSCC tumor density, quantified by CT radiomics, is associated with LC after radiochemotherapy and HPV status." | ( Bogowicz, M; Guckenberger, M; Ikenberg, K; Moch, H; Riesterer, O; Stieb, S; Studer, G; Tanadini-Lang, S, 2017) |
| "Due to the high incidence of recurrent squamous cell carcinoma of the head and neck and the toxicity profile of current salvage regimens, there is a need for tolerable and effective treatment options." | ( Bellile, E; Bradford, CR; Chepeha, DB; Eisbruch, A; Manohar, PM; Pearson, AT; Prince, ME; Sapir, E; Shuman, AG; Spector, ME; Swiecicki, PL; Wolf, GT; Worden, FP, 2017) |
| "Treatment of HNSCC with the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924), which inhibits all cullin-based ligases, induces significant rereplication and inhibits HNSCC cell proliferation in culture and HNSCC xenografts in mice." | ( Abbas, T; Allak, A; Benamar, M; Guessous, F; Jameson, MJ; Read, PW; Vanderdys, V, 2018) |
| "FMISO-PET/CT images of further 25 HNSCC patients were acquired at four time-points before and during radiochemotherapy (RCHT)." | ( Bandurska-Luque, A; Baumann, M; Kotzerke, J; Krause, M; Löck, S; Perrin, R; Seidlitz, A; Steinbach, J; Troost, EGC; Zips, D; Zöphel, K; Zschaeck, S, 2017) |
| "In order to improve therapy for head and neck squamous cell carcinoma (HNSCC), biomarkers associated with local and/or distant tumor relapses and cancer drug resistance are urgently needed." | ( Gao, H; Jin, P; Li, S; Li, Y; Liao, S; Liu, S; Ren, B; Stroncek, D; Su, XJ; Xu, Z; Zeng, Q; Zhai, YX, 2017) |
| "Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2)." | ( Alterio, D; Azzarello, G; Bertoni, F; Bidoli, P; Bonetti, A; Bunkheila, F; Campostrini, F; Casanova, C; Chiappa, F; Cipani, T; Codecà, C; D'Ambrosio, C; Da Corte, D; Emiliani, E; Ferrari, D; Foa, P; Frattegiani, A; Gava, A; Ghi, MG; Guaraldi, M; Koussis, H; Loreggian, L; Massa, E; Mastromauro, C; Mione, CA; Morelli, F; Niespolo, RM; Nolè, F; Orecchia, R; Paccagnella, A; Parisi, S; Pieri, G; Polsinelli, M; Rossetto, C; Rulli, E; Valduga, F; Verri, E, 2017) |
| "Randomized patients with R/M HNSCC and progression following ≥2 cycles of platinum therapy received afatinib (40 mg/day) or methotrexate (40 mg/m2/week)." | ( Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB, 2017) |
| "Patients with stage III, IVA, or IVB LAHNSCC were enrolled in this study to evaluate the efficacy of S-1 compared with UFT as adjuvant chemotherapy after curative CRT in the ACTS-HNC study." | ( Beppu, T; Fujii, M; Hanamure, Y; Hasegawa, Y; Higaki, Y; Iwae, S; Kawabata, K; Kohno, N; Kubota, A; Nagahara, K; Nakatani, E; Nakatani, H; Taguchi, T; Takemura, H; Terada, T; Teramukai, S; Tomita, K; Tsukahara, K; Yoshino, K, 2018) |
| "For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment." | ( Ahn, MJ; Chang, WJ; Choi, MK; Hong, JY; Jung, HA; Kim, HS; Kim, MJ; Kim, SM; Park, K; Sun, JM, 2019) |
| "Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study." | ( Bohlander, SK; Budhani, P; Butt, S; Caporiccio, L; Chaplin, JM; Chiorean, EG; Curran, MA; Grénman, RA; Hart, CP; Hicks, KO; Hong, CR; Hunter, FW; Jalal, SI; Jamieson, SM; Kakadia, PM; Kee, D; Knowlton, NS; Kondratyev, MK; Lee, TW; Li, D; Liu, A; Lynch, CR; Macann, AM; McIvor, NP; McKee, TD; Nemunaitis, JJ; Poonawala-Lohani, N; Print, CG; Senzer, NN; Shome, A; Tsai, P; Wilson, WR; Wong, WW; Wouters, BG; Zaidi, M, 2018) |
| "In treating patients with HNSCC, DSF may contribute to improved HNSCC patient's survival." | ( Cho, JG; Go, YY; Park, YM; Shin, SH; Song, JJ; Woo, JS, 2018) |
| "Patients with stage III to IVb HNSCC who had been treated nonsurgically with RT and cisplatin or cetuximab from 2000 to 2016 within the Veterans Health Affairs system were identified." | ( Aggarwal, C; Anna Park, YH; Bates, SE; Bauml, JM; Cohen, RB; Damjanov, N; Di Stefano, J; Fojo, T; Knepley, C; Langer, CJ; Limaye, S; Mamtani, R; Sigel, K; Vinnakota, R; Wisnivesky, J, 2019) |
| "Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has been a longstanding challenge for head and neck oncologists, and current treatments still have limited efficacy." | ( An, S; Ban, MJ; Byeon, HK; Kee, H; Kim, DH; Kim, JH; Kim, JW; Koh, YW; Yang, J; Yang, YJ, 2018) |
| "Patients with untreated stage II-IVA HNSCC received rapamycin for 21 days (day 1, 15 mg; days 2-12, 5 mg) prior to definitive treatment with surgery or chemoradiation." | ( Callejas-Varela, JL; Day, TA; Godwin, K; Gutkind, JS; Harismendy, O; Kompelli, A; Lippman, SM; Martin, D; Matheus, MG; Molinolo, AA; O'Brien, PE; Shirai, K; Sood, AJ; Szabo, E; Van Waes, C; Vick, JA; Vitale-Cross, L; Wang, Z; Wu, X, 2019) |
| "Adult patients with R/M-HNSCC, who initiated systemic therapy between 1 September 2011 and 31 December 2014 and followed through 31 December 2015, were identified from iKnowMed electronic-health-records database (McKesson Specialty Health) supplemented with manual chart-abstraction." | ( Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E, 2019) |
| "Consecutive patients with HNSCC referred for a pretreatment FDG-PET/CT were retrospectively included and followed up for a minimum of 2 years." | ( Abgral, R; Bourhis, D; Delcroix, O; Gobel, Y; Guezennec, C; Orlhac, F; Robin, P; Rousset, J; Salaün, PY; Schick, U, 2019) |
| "In patients with HNSCC in particular, swallowing may be difficult or completely prevented, therefore it is necessary to resort to alternative routes of administration instead of the oral one." | ( Gennari, A; Rondonotti, D, 2018) |
| "We found that treatment of all HNSCC cells with Gefitinib and Erlotinib, two Food Drug Administration-approved EGFR inhibitors, blocked the activity of Akt/mammalian target of the rapamycin (mTOR) and extracellular signal-regulated kinase, two crucial downstream effectors of EGFR, but up-regulated IKKβ/NF-κB signalling." | ( Choi, EY; Cullen, KJ; Dan, H; Lapidus, RG; Li, Z; Liao, J; Liu, X; Yang, Z, 2019) |
| "CSCs and non-stem HNSCC cells were treated with metformin and cisplatin alone, and in combination, and cell proliferation levels were measured through MTS assays." | ( Abhold, E; Altuna, X; Honda, CO; Honda, TK; Kim, E; Kuo, SZ; Li, WT; Ongkeko, WM; Wang-Rodriguez, J, 2019) |
| "Eighty-two patients with HNSCC treated with surgery and postoperative IMRT with or without chemotherapy from October 15, 2008 to December 31, 2014 that had post-tx PET/CT within 6 months of completing IMRT were included." | ( Avril, NE; Awan, MJ; Chang, T; Chen, N; Fowler, N; Lavertu, P; Li, Y; Machtay, M; Rezaee, R; Wasman, J; Yao, M; Zender, C, 2019) |
| "Tumor volume in locally advanced head and neck squamous cell carcinomas (LAHNSCC) treated by induction chemotherapy (ICT) and followed by radiochemotherapy (RCT) was measured." | ( Berliner, C; Bier, J; Bohlen, M; Busch, C-; Bußmann, L; Forterre, F; Münscher, A; Sehner, S, 2019) |
| "Data of patients with LAHNSCC treated by ICT consisting of docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by definite RCT were retrospectively analyzed." | ( Berliner, C; Bier, J; Bohlen, M; Busch, C-; Bußmann, L; Forterre, F; Münscher, A; Sehner, S, 2019) |
| "Patients with newly diagnosed T3-T4 laryngeal squamous cell carcinoma treated with definitive RT from 2004 to 2014 were reviewed." | ( Anderson, C; Graham, M; Mallak, N; Mayo, Z; Menda, Y; Mott, SL; Seyedin, SN, 2019) |
| "The effects of hypoxia-treated HNSCC cells on the migration and polarization of macrophages were analyzed." | ( Cai, Y; Han, S; Han, W; Hu, Q; Ran, J; Song, C; Tang, C; Wang, Y; Wei, Z; Xu, W; Yin, X; Zou, H, 2019) |
| "Treatment of HNSCC cell lines with BYL719 significantly reduced AKT activation and suppressed tumor growth." | ( Alvarado, D; Duvvuri, U; Godse, NR; Grandis, JR; Hedberg, ML; Kemp, C; Khan, NI; Kim, S; Kulkarni, S; LaVallee, T; Meister, KS, 2019) |
| "Cisplatin, most frequently used for HNSCC treatment, activates mitochondria-dependent apoptosis through the BCL-2 family proteins." | ( Britt, EL; Harada, H; Kim, SW; Leek, K; Raman, S; Sheehy, CH, 2019) |
| "Head and Neck Squamous Cell Carcinoma (HNSCC) is a heterogeneous disease of significant mortality and with limited treatment options." | ( Buck, MJ; Garrett-Sinha, LA; Glathar, A; Gluck, C; Nowak, N; Sinha, S; Tsompana, M, 2019) |
| "Human HNSCC cell lines were treated with cisplatin or oxaliplatin, then assessed for markers associated with immunogenic cell death (ICD) and antigen processing." | ( Hodge, JW; Padget, M; Park, SJ; Schmitt, NC; Silvin, C; Van Waes, C; Xiao, R; Ye, W, 2019) |
| "Treatment of HNSCC cells with platinum chemotherapy appears to induce some features of anti-tumor immunity, which may be enhanced by anti-PD-1 therapy." | ( Hodge, JW; Padget, M; Park, SJ; Schmitt, NC; Silvin, C; Van Waes, C; Xiao, R; Ye, W, 2019) |
| "Standard treatment for locally advanced head and neck squamous cell carcinoma (LAHNSCC) consists mainly of concurrent chemoradiation (CCR) but induction chemotherapy (IC) by docetaxel-cisplatin-fluorouracil (TPF), followed by CCR, is a strong option." | ( Fayette, J; Gau, M; Karabajakian, A; Neidhardt, EM; Reverdy, T, 2019) |
| "Management of locally advanced head and neck squamous cell carcinoma (HNSCC) requires a multi-prong approach comprising surgery, radiation and/or chemotherapy, yet outcomes are limited." | ( Carvalho, AL; Iyer, NG; Leong, HS; Lim, SK; Melendez, ME; Ramos, CRN; Rodrigues-Junior, DM; Tan, DSW; Tan, SS; Vettore, AL; Viana, LS, 2019) |
| "Patients with head and neck squamous cell carcinoma (HNSCC) can experience severe symptom burden and/or difficulty swallowing, leading to problems with treatment adherence/administration." | ( Clement, PM; Cohen, EEW; Cupissol, D; de Souza Viana, L; Fayette, J; Gauler, T; Geng, Y; Geoffrois, L; Guigay, J; Haddad, R; Keilholz, U; Kornek, G; Licitra, L; Machiels, JP; Melichar, B; Rauch, D; Ribaldo Nicolau, U; Rolland, F; Tahara, M; Vermorken, J; Zanetta-Devauges, S; Zografos, E, 2019) |
| "Patients with HNSCC who were treated with (chemo)radiotherapy between 2008 and 2017 and underwent (i) baseline and (ii) response assessment PET-CT and (iii) second-look PET-CT following incomplete (positive or equivocal scan) response were included." | ( Arunsingh, M; Dyker, KE; Prestwich, RJD; Scarsbrook, AF; Vaidyanathan, S; Zhong, J, 2020) |
| "Five hundred sixty-two patients with HNSCC underwent response assessment PET-CT at a median of 17 weeks post-radiotherapy." | ( Arunsingh, M; Dyker, KE; Prestwich, RJD; Scarsbrook, AF; Vaidyanathan, S; Zhong, J, 2020) |
| "However, only one of the six HNSCC cell lines studied exhibited enhanced sensitivity to NK cell‑mediated killing following sulforaphane treatment, suggesting that this may not be a general mechanism of sulforaphane chemopreventive activity in HNSCC." | ( Bauman, JE; Grandis, JR; Hu, L; Johnson, DE; Lee, ED; Li, H, 2019) |
| "T-cell functions of CDDP-treated HNSCC patients were comparable to those of healthy donors and CDDP-untreated HNSCC patients." | ( Harabuchi, S; Harabuchi, Y; Hayashi, R; Kobayashi, H; Kosaka, A; Kumai, T; Nagata, M; Nagato, T; Ohara, K; Ohara, M; Ohkuri, T; Oikawa, K; Yajima, Y, 2020) |
| "Addition of AKT blockade improves anti-HNSCC efficacy of anti-Src therapy, and co-delivery of capivasertib and saracatinib by tumor-targeting NPs has the potential to achieve better treatment outcomes than the free drug combination." | ( Lang, L; Shay, C; Teng, Y; Wang, X; Xiong, Y; Zhao, X, 2019) |
| "Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide and represents a heterogeneous group of tumors, the majority of which are treated with a combination of surgery, radiation, and chemotherapy." | ( Ho, C; Jones, MR; Jones, SJM; Laskin, J; Lim, HJ; Majounie, E; Marra, MA; Pleasance, E; Renouf, DJ; Wee, K; Williamson, LM; Yip, S, 2020) |
| "Patients with Fanconi anemia with HNSCC are not eligible for conventional therapies due to high toxicity in healthy cells, predominantly hematotoxicity, and the only treatment currently available is surgical resection." | ( Antonio Casado, J; Arango, D; Bueren, JA; Carrascoso-Rubio, C; Carreras-Puigvert, J; González, A; Helleday, T; Lasa, A; Lerma, E; Martínez-Barriocanal, Á; Minguillón, J; Montanuy, H; Nieto, R; Ramírez, MJ; Riera, P; Rovirosa, L; Surrallés, J, 2020) |
| "Chemotherapy in head and neck squamous cell carcinoma (HNSCC) has many systemic side effects, as well as hypoxia-induced chemoresistance." | ( Cai, Y; Cheng, W; Han, W; Ran, J; Song, C; Tang, C; Wang, Y; Wei, Z; Xu, W; Zou, H, 2020) |
| "Patients with head and neck squamous cell carcinoma with locally advanced disease often require multimodality treatment with surgery, radiotherapy and/or chemotherapy." | ( Forster, M; Good, J; Harrington, K; Kirkham, A; Kong, A; Llewellyn, L; Mant, R; Mehanna, H; Middleton, G; Murray, P; Parish, J; Sacco, J; Savage, J; Schipani, S; Spruce, R; Yap, C, 2020) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide, and is an aggressive type of cancer that is associated with a high recurrence rate, metastasis and poor treatment outcomes." | ( Cacciapuoti, G; Carriero, MV; Minopoli, M; Mosca, L; Pagano, M; Porcelli, M; Vitiello, F, 2020) |
| "Head and neck squamous cell carcinoma (HNSCC) of unknown primary represents a diagnostic and therapeutic challenge for treating physicians." | ( Delidis, A; Economopoulou, P; Giotakis, E; Kalkanis, D; Maragkoudakis, P; Psyrri, A; Sakagiannis, G; Zacharatou, A, 2020) |
| "Head and neck squamous cell carcinoma (HNSCC) is one of the most fatal malignancies worldwide and despite using various therapeutic strategies for the treatment of HNSCC, the surveillance rate is low." | ( Atri, S; Hodjat, M; Nasoohi, N, 2021) |
| "Human HNSCC cell lines were treated with Azacitidine and Trichostatin A to investigate their effects on telomerase gene expression and activity." | ( Atri, S; Hodjat, M; Nasoohi, N, 2021) |
| "Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit." | ( Ahn, MJ; Burtness, B; Cheng, JD; Chirovsky, DR; Cohen, EEW; Dinis, J; Ellison, MC; Harrington, KJ; Le Tourneau, C; Licitra, LF; Mach, N; Machiels, JH; Mehra, R; Soria, A; Soulières, D; Swaby, RF, 2021) |
| "Forty patients with LAHNSCC were included and 50% received induction chemotherapy." | ( A Moez, M; Abo-Madyan, Y; Atef, H; Mashhour, K; Selim, A; Zawam, H, 2020) |
| "Patients with LA-HNSCC who underwent definitive or postoperative cisplatin-based chemoradiotherapy (CRT) were included." | ( Jiarpinitnun, C; Ngamphaiboon, N; Nongnuch, A; Patimarattananan, T; Pattaranutaporn, P; Unwanatham, N, 2021) |
| "All patients with node-positive head and neck squamous cell carcinoma (HNSCC) treated with (chemo)radiotherapy between January 2013 and September 2017 were identified." | ( Dempsey, MF; Grose, D; Hendry, F; James, A; Lamb, C; Lau, YC; Paterson, C; Rizwanullah, M; Rulach, R; Schipani, S; Stobo, D; Wilson, C; Zhou, S, 2020) |
| "Between 2013 and 2019, advanced-staged HNSCC patients were prospectively included, underwent (chemo) radiotherapy with curative intent and planned for both pre-treatment and intratreatment sequential 18F-FDG-PET/CT, 18F-FDG-PET/MRI and thereafter MRI (including DWI/DCE)." | ( Boellaard, R; Castelijns, JA; de Bree, R; de Graaf, P; Koopman, T; Leemans, CR; Martens, RM; Noij, DP; Vergeer, MR; Zwezerijnen, G, 2021) |
| "Cisplatin-resistant oral squamous cell carcinoma (OSCC) cells acquire stem-like characteristics and are difficult to treat." | ( Jha, A; Kashyap, T; Mishra, P; Mishra, R; Nagini, S; Nath, N, 2020) |
| "Targeted therapies in the treatment of head and neck squamous cell carcinoma (HNSCC) are subject to extensive research." | ( Aderhold, C; Birk, R; Huber, L; Jungbauer, F; Knuettel, M; Kramer, B; Lammert, A; Rotter, N; Scherl, C, 2020) |
| "Head and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated." | ( Balermpas, P; Belka, C; Bergmann, T; Fietkau, R; Göhler, T; Große-Thie, C; Guntinas-Lichius, O; Hahn, D; Hautmann, MG; Hecht, M; Messinger, D; Orlowski, K; Reichert, D; Stenzel, KG; von der Grün, J; Welslau, M; Weniger, S; Wolber, P, 2020) |
| "A total of 41 HNSCC patients with positive or equivocal posttreatment contrast-CT were eligible for post-RCT-ND." | ( Arnold, C; Dejaco, D; Kofler, B; Moser, P; Riechelmann, H; Riedl, D; Schartinger, VH; Steinbichler, TB; Uprimny, C; Virgolini, I; Widmann, G, 2020) |
| "For this purpose, oral squamous cell carcinoma cell CAL27 was cultured in vitro, and cells were treated with ethyl acetate extract of peony seed coat at different concentrations." | ( Qing, S; Ren, S, 2020) |
| "Data from 118 consecutive HNSCC patients, treated between 2012 and 2015, were evaluated prospectively." | ( Andrade, TU; Bissoli, NS; Campos, FV; de Oliveira, KG; Gouvea, SA; Podestá, JRV; Thebit, MM; Zeidler, SLVV, 2021) |
| "Patients with recurrent or metastatic HNSCC treated with the EXTREME regimen were retrospectively analyzed." | ( Fujiwara, Y; Fukuda, N; Hayashi, N; Mitani, H; Nakano, K; Ohmoto, A; Ono, M; Sato, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yunokawa, M, 2021) |
| "Current chemotherapy for head and neck squamous cell carcinomas (HNSCCs) are based on cisplatin, which is usually associated to severe side effects." | ( Biancalana, L; Mapanao, AK; Marchetti, F; Santi, M; Voliani, V, 2021) |
| "Patients with oral squamous cell carcinoma (OSCC) bone invasion are surgically treated with bone resection, which results in severe physical and psychological damage." | ( Chung, WY; Jung, MJ; Kim, H; Kim, KR; Lee, SK; Park, J; Park, KK; Son, SH, 2021) |
| "Advanced cutaneous squamous cell carcinoma of the head and neck (CSCCHN) is associated with poor outcome despite multimodality therapy." | ( Dorman, A; Fliss, DM; Gutfeld, O; Horowitz, G; Kampel, L; Muhanna, N, 2021) |
| "Radiotherapy (RT) has a central role in head and neck squamous cell carcinoma (HNSCC) treatment." | ( Bamps, M; Dok, R; Glorieux, M; Nuyts, S, 2021) |
| "Head and neck squamous cell carcinoma (HNSCC) cells with or without melatonin treatment were used as a research platform." | ( Jensen, C; Lang, L; Loveless, R; Prieto-Dominguez, N; Shay, C; Teng, Y; Xiong, Y, 2021) |
| "Patients with head and neck squamous cell carcinoma (HNSCC) are characterized by aberrant DNA repair pathways, including nucleotide excision repair (NER), base excision repair (BER) and DNA double-strand breaks (DSBs) repair and these deregulated repair mechanisms are implicated in both the pathogenesis of the disease and the outcome of therapy." | ( Economopoulou, P; Moutafi, M; Psyrri, A; Rimm, D, 2021) |
| "Refractory and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) generally does not respond to PD-1 inhibitor monotherapy." | ( Babiker, H; Brana, I; Calvo, E; Crittenden, M; Feng, M; Formenti, S; Fury, M; Garrido, P; Giralt, J; Hervás-Morón, A; Li, J; Lowy, I; Mahadevan, D; Mathias, M; Mohan, KK; Moreno, V; Owonikoko, T; Papadopoulos, KP; Rischin, D; Soria, A; Stankevich, E, 2021) |
| "Patients with R/M HNSCC refractory to at least first-line therapy and for whom palliative RT is clinically indicated received cemiplimab plus RT, cyclophosphamide, and GM-CSF." | ( Babiker, H; Brana, I; Calvo, E; Crittenden, M; Feng, M; Formenti, S; Fury, M; Garrido, P; Giralt, J; Hervás-Morón, A; Li, J; Lowy, I; Mahadevan, D; Mathias, M; Mohan, KK; Moreno, V; Owonikoko, T; Papadopoulos, KP; Rischin, D; Soria, A; Stankevich, E, 2021) |
| "To discover novel strategies against head and neck squamous cell carcinoma (HNSCC), we performed genomics, metabolomics and RNA omics studies in HNSCC cells treated with EZH2 inhibitors." | ( Chen, J; Chen, W; Li, Y; Wang, Q; Wang, X; Wei, Y; Wen, Y; Xu, Q; Xu, X; Yan, M; Yang, X; Zhang, J, 2021) |
| "Patients with HPV-negative TP53 mutant HNSCC have the worst prognosis, necessitating additional agents for treatment." | ( Alam, MM; Burnett, C; Khandelwal, AR; Marin Fermin, J; Maxwell, CO; Moore-Medlin, T; Nathan, CO; Rong, X; Spiller, PT, 2022) |
| "The three HNSCC cell lines SCC25, Cal27 and FaDu were treated with zerumbone, radiation and/or cisplatin." | ( Brunner, M; Heiduschka, G; Jank, BJ; Kotowski, U; Schmid, R; Schnoell, J; Stanek, V; Stanisz, I, 2022) |
| "Treatment of wild-type H-Ras HNSCC cell lines in vitro with tipifarnib reduced cell growth and increased levels of defarnesylated H-Ras in a dose-dependent manner." | ( Chen, Z; Chen, ZG; El-Deiry, M; Griffith, CC; Nannapaneni, S; Patel, M; Saba, NF; Shin, DM; Shu, L; Sun, Y; Wang, D; Wang, X, 2021) |
| "Treatment decisions for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are complicated, and multi-modal treatments are usually indicated." | ( Ahn, HK; Choi, JH; Kang, EJ; Keam, B; Kim, HJ; Kim, HR; Kim, JS; Kim, MK; Kim, SB; Kwon, JH; Lee, JB; Lee, KE; Lee, KW; Lee, YG; Park, KU; Shin, SH; Yun, HJ, 2022) |
| "Older LA-HNSCC patients had aggressive tumor characteristics and received less intensive treatment, resulting in poor survival." | ( Ahn, HK; Choi, JH; Kang, EJ; Keam, B; Kim, HJ; Kim, HR; Kim, JS; Kim, MK; Kim, SB; Kwon, JH; Lee, JB; Lee, KE; Lee, KW; Lee, YG; Park, KU; Shin, SH; Yun, HJ, 2022) |
| "Three HNSCC cell lines were treated with galunisertib alone, or in combination with radiation." | ( Campion, NJ; Haas, M; Heiduschka, G; Jank, BJ; Kadletz-Wanke, L; Lenz, T; Macfelda, K; Schnoell, J, 2022) |
| "Further evaluation of its use in HNSCC therapy is warranted." | ( Haas, M; Heiduschka, G; Jank, BJ; Kadletz-Wanke, L; Lenz, T, 2022) |
| "Head and neck squamous cell carcinoma (HNSCC) is a lethal disease with a terrible prognosis, accounting for more than 900,000 new cases and 500,000 deaths each year, nevertheless, its pharmacotherapy is rather limited." | ( Dong, X; Du, L; Hu, M; Li, M; Liang, D; Ma, Z; Wang, J; Yu, C, 2022) |
| "Radiotherapy (RT) against head and neck squamous cell carcinomas (HNSCC) may lead to severe toxicity in 30-40% of patients." | ( Bachmann, P; Bastogne, T; Bois, P; Claude, L; Deneuve, S; Duclos, M; Ferella, L; Foray, N; Girodet, D; Iacovelli, NA; Mirjolet, C; Nokovitch, L; Pereira, S; Poupart, M; Rancati, T; Roux, PE; Zrounba, P, 2023) |
| "Treatment of oral squamous cell carcinoma (OSCC) is based on clinical exam, biopsy, and a precise imaging-based TNM-evaluation." | ( Burian, E; Callahan, N; Froelich, MF; Gassert, FG; Makowski, MR; Palla, B; Pyka, T; Rübenthaler, J; Schmid, A; von Schacky, CE; Wolff, C, 2022) |
| "We investigated whether in human head and neck squamous cell carcinoma (HNSCC) high levels of expression of stress keratin 17 (K17) are associated with poor survival and resistance to immunotherapy." | ( Bruce, JY; Dinh, HQ; Fitzpatrick, MB; Golfinos, AE; Gronski, E; Harari, PM; Hayes, M; Hu, R; Keske, A; Kimple, RJ; Lambert, PF; Lee, D; Lozar, T; Sondel, PM; Wang, W; Ward-Shaw, E; Xu, J, 2022) |
| "We demonstrate that K17 expression in HNSCC contributes to immune evasion and resistance to ICB treatment by broadly altering immune landscapes of tumors." | ( Bruce, JY; Dinh, HQ; Fitzpatrick, MB; Golfinos, AE; Gronski, E; Harari, PM; Hayes, M; Hu, R; Keske, A; Kimple, RJ; Lambert, PF; Lee, D; Lozar, T; Sondel, PM; Wang, W; Ward-Shaw, E; Xu, J, 2022) |
| "HPV-positive HNSCC cell lines were treated with the FDA approved ErbB kinase inhibitor, Afatinib or FDA-approved PI3K inhibitor, Copanlisib, alone or in combination, and phosphorylation and total protein levels of cells were assessed by Western blot analysis." | ( Carter-Cooper, B; Cullen, KJ; Dan, H; Fan, X; Gaykalova, DA; Lapidus, RG; Liao, J; Mehra, R; Schumaker, L; Yang, Z, 2022) |
| "The development of drug resistance in oral squamous cell carcinoma (OSCC) that frequently leads to recurrence and metastasis after initial treatment remains an unresolved challenge." | ( Chen, PM; Cho, CY; Chuang, SE; Huang, WC; Jang, TH; Lin, SC; Lo, GH; Tung, SL; Wang, LH; Yang, YY; Yen, TC, 2022) |
| "CAP shows strong cytostatic effects in HNSCC cell lines that can be increased by concurrent cisplatin treatment, suggesting that CAP may enhance the therapeutic efficacy of low dose cisplatin." | ( Becker, S; Brunner, TF; Harréus, U; Morfill, G; Probst, FA; Schwenk-Zieger, S; Troeltzsch, M; Welz, C; Zimmermann, JL, 2022) |
| "Head and neck squamous cell carcinoma (HNSCC) remains a deadly disease despite concerted efforts to improve its diagnosis and treatment in recent decades." | ( Lang, L; Teng, Y, 2022) |
| "Adult patients with biopsy-proven HNSCC scheduled for standard-of-care surgery were enrolled in a clinical trial and underwent systemic administration of 89Zirconium-panitumumab and panitumumab-IRDye800 followed by preoperative 89Zr-pan PET/CT and intraoperative fluorescence imaging." | ( Azevedo, EC; Baik, FM; Castillo, J; Chin, FT; Colevas, AD; Duan, H; Ferri, V; Freeman, L; Hom, M; Iagaru, A; Kaplan, MJ; Koran, ME; Lee, YJ; Martin, BA; Raymundo, RC; Rosenthal, EL; Shen, B; Valencia, A; van den Berg, NS; Zhou, Q, 2022) |
| "In patients with HNSCC before any treatment such as definitive radio (chemo)therapy or oncologic surgery followed by adjuvant RT, baseline PLR correlated with MTV and TLG but not with SUV." | ( Aebersold, DM; Alberts, I; Bojaxhiu, B; Elicin, O; Rominger, A; Shelan, M; Sinovcic, D; Templeton, AJ; Wartenberg, J; Zaugg, K, 2022) |
| "Treatment of oral squamous cell carcinoma (OSCC) cells with the synthetic vitamin A derivative, fenretinide (4HPR), induces numerous cancer-preventive effects including suppression of basement membrane invasion, elimination of anchorage-independent growth, disruption of actin cytoskeletal components and inhibition of the invasion-enabling focal adhesive kinase." | ( Bissonnette, C; Din, C; Lin, YX; Liu, Y; Mallery, SR; Nieto, K; Pei, P; Schwendeman, SP; Shea, FF; Spinney, R; Wang, D, 2022) |
| "Despite therapeutic advancements, oral cavity squamous cell carcinoma (OCSCC) remains a difficult disease to treat." | ( Agrawal, N; Alonso, MJ; Aydin, E; Bettegowda, C; Birdi, A; Cantin, S; Conway, P; D'Cruz, A; Flaum, B; Gallia, GL; Goldberg, ER; Goldberg, M; Goldberger, S; Hasina, R; Izumchenko, E; Laporte, B; Lingen, MW; London, NR; Manzi, A; Melville, J; Mishra, V; O'Neill, SE; Pearson, AT; Rosenberg, AJ; Sandulache, V; Shum, J; Singh, A; Soto, A; Vidal, A; Young, S; Zhavoronkov, A, 2022) |
| "Head and neck squamous cell carcinoma (HNSCC) exhibits a high mortality and morbidity rate, and its treatment is facing clinical challenges." | ( Cai, S; Chen, X; Ding, Q; Hong, W; Liu, W; Lu, J; Qiu, S; Wang, L, 2022) |
| "Patients with HPV-unrelated head and neck squamous cell carcinoma (HPV-unrelated HNSCC) show only modest benefit from treatment with PD-1 inhibitors (PD-1i)." | ( Bell, RB; Crittenden, M; Gough, M; Young, K, 2022) |
| "Paired pre- and post-treatment primary HNSCC tumor samples were stained for CD8+ and FoxP3+." | ( Alnemri, A; Argiris, A; Curry, J; Fiorella, M; Harshyne, L; Johnson, J; Linnenbach, A; Luginbuhl, A; Martinez-Outschoorn, U; Philips, R; Solomides, C; South, A; Stapp, R; Sussman, S; Tuluc, M, 2023) |
| "(2) Methods: Using human HNSCC cell line models and a mouse oral cancer syngeneic model, we have analyzed the ability of the EXTREME regimen (combination therapy using the anti-EGFR cetuximab antibody and platinum-based chemotherapy) to modify the immunogenicity of HNSCC cells." | ( Borel, C; Bour, C; De Azevedo, J; Devignot, V; Gaiddon, C; Jung, AC; Mellitzer, G; Mourtada, J; Pencreach, E; Schultz, P, 2022) |
| "Tumour recurrences after treatment of head and neck squamous cell carcinoma (HNSCC) are more likely to originate from regions of high-baseline FDG-PET uptake." | ( Aren, E; Berry, M; Deshpande, S; Estall, V; Fowler, A; Jameson, MG; Johnston, M; Lee, M; Trada, Y, 2023) |
| "Treatment regimens for head and neck squamous cell carcinoma (HNSCC) typically include cisplatin and radiotherapy and are limited by toxicities." | ( Cohen, MS; Kovatch, KJ; Pearce, R; Prince, ME; Spielbauer, KK; Subramanian, C; Timmermann, BN, 2022) |
| "Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD, respectively)." | ( Allen, BG; Anderson, CM; Beardsley, RA; Bodeker, KL; Buatti, JM; Cl, H; Davidson, S; Dunlap, NE; Fairbanks, R; Furqan, M; Holmlund, JT; Jetton, JG; Lee, CM; Mapuskar, KA; Monga, V; Mott, SL; Pearce, A; Petronek, MS; Pitre, L; Pulliam, CF; Saunders, DP; Spitz, DR; Steinbach, EJ; Vasquez Martinez, G; Zepeda-Orozco, D, 2023) |
| "We examined 53 patients with HNSCC who underwent 4D PCT, DWI and PET-CT before chemoradiotherapy." | ( Doai, M; Matoba, M; Nagata, H; Nishino, Y; Ota, K; Tsuchiya, H; Tuji, H, 2023) |
| "Among patients with R/M HNSCC treated with IO in this retrospective single-institution cohort, Cox regression was used to compare overall survival (OS) for those with platinum-refractory disease and those treated in the first-line setting with OS from KEYNOTE-040/048, respectively." | ( Campbell, SR; Geiger, JL; Koyfman, S; Lopetegui-Lia, N; Roof, L; Schwartzman, LM; Silver, N; Woody, NM; Yalamanchali, A; Yang, K; Yilmaz, E, 2023) |
| "Two human HNSCC cell lines (Cal27, FaDu) received five different treatments: TTFields, RT +/- TTFields and RT + simultaneous cisplatin +/- TTFields." | ( Abraham, Y; Adeberg, S; Debus, J; Franke, H; Held, T; Hess, J; Hörner-Rieber, J; Huber, PE; Lopez Perez, R; Naveh, A; Regnery, S; Trinh, T, 2023) |
| "In a retrospective study of 66 R/M HNSCC patients from 2015 to 2020, opioid dosage, calculated as mean morphine milligram equivalent per day, was assessed on the day of anti-PD-1 monoclonal antibody (mAb) treatment and most recent prior visit." | ( Acharya, R; Anderson, JL; Delgoffe, GM; Ferris, RL; Harris, AL; Hsieh, RW; Li, J; Menk, AV; Nilsen, ML; Scheff, NN; Swartz, A; Zandberg, DP, 2023) |
| "HPV-positive HNSCC cells showed significant prolonged G2-M cell cycle arrest and aberrant chromosome formation under interstrand crosslinker treatment." | ( Deng, Y; Hu, W; Liu, Q; Liu, T; Luo, Y; Ma, L; Meng, H; Ren, Q; Wei, L; Zuo, N, 2023) |
| "Head and neck squamous cell carcinoma (HNSCC) is a significant public health problem, with a need for novel approaches to chemoprevention and treatment." | ( Iwenofu, OH; Jordanides, PP; Lamenza, FF; Oghumu, S; Pracha, H; Roth, P; Ryan, NM; Siddiqui, A; Springer, A; Upadhaya, P, 2023) |
| "Feline oral squamous cell carcinoma (FOSCC) is an aggressive cancer in domestic cats that has no effective treatment option when advanced." | ( Bryan, JN; Burton, JH; Cermak, J; Chu, S; Lee, S; Marquardt, TM; Noall, L; Rogic, AM; Thombs, LA, 2023) |
| "In the HNSCC-15-132 trial, sequential application of the PD‑1 inhibitor pembrolizumab to chemoradiotherapy was not significantly, but numerically superior to concomitant application." | ( Gostian, AO; Hecht, M; Linxweiler, M; Schnellhardt, S, 2023) |
| "We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel." | ( Chen, L; Gelblum, D; Han, J; Hesse, J; Kang, JJ; Lee, NY; McBride, SM; Michel, L; Raab, G; Riaz, N; Shamseddine, A; Sherman, EJ; Tsai, CJ; Wong, RJ; Yu, Y; Zakeri, K, 2023) |
| "The treatment of oral squamous cell carcinoma (OSCC) includes systemic chemotherapy and is associated with aggressive side effects on patients." | ( Aboushelib, MN; Al-Wakeel, E; Badawi, MF; Elsaady, SA, 2023) |
| "All adults with histologically proven HNSCC who were treated with curative intent between January 1, 2006, and December 31, 2019, and achieved a complete response on imaging at 3 to 6 months were included." | ( Abgral, R; Clément, C; Gujral, DM; Le Gal, G; Le Pennec, R; Leclère, JC; Maheo, C; Marianowski, R; Salaun, PY; Schick, U, 2023) |
| "Forty-one patients with HNSCC were randomized to cisplatin plus olaparib (arm A), olaparib alone (arm B), no treatment (arm C) or durvalumab plus olaparib (arm D)." | ( Anastasiou, M; Aung, TN; Delides, A; Economopoulou, P; Fernandez, AI; Foukas, PG; Fountzilas, G; Gagari, E; Gavrielatou, N; Giotakis, E; Gkolfinopoulos, S; Gkotzamanidou, M; Koliou, GA; Kotsantis, I; Kougioumtzopoulou, A; Kouloulias, V; Kyrodimos, E; Lianidou, E; Moutafi, M; Palialexis, K; Panayiotides, IG; Papadimitriou, NG; Papaxoinis, G; Pectasides, D; Perisanidis, C; Poulios, C; Psyrri, A; Rimm, DL; Shafi, S; Strati, A; Xirou, V; Yaghoobi, V, 2023) |
| "When evaluated in patients with HNSCC who were treated with primary RCTx, these genes were predictive for LRC." | ( Baumann, M; Besso, MJ; Bitto, V; Koi, L; Krause, M; Kurth, I; Linge, A; Löck, S; Möbius, L; Overgaard, J; Pfeifer, M; Valentini, C; Weise, C; Yaromina, A; Zips, D, 2023) |
| "For the treatment of patients with oral squamous cell carcinoma (OSCC), the imaging of cervical lymph nodes and the evaluation of metastastic progression are of great significance." | ( Butch, CJ; Li, Y; Shi, J; Wang, Y; Wang, Z; Xie, D; Zhu, YP, 2023) |
| "We retrospectively collected data of LA-HNSCC patients treated at our Institution from 2008 to 2019." | ( Alfieri, S; Barretta, F; Bergamini, C; Calareso, G; Cavalieri, S; Colombo, E; Cosmai, L; De Feo, G; Di Pede, P; Franceschini, M; Gandelli, M; Guglielmo, M; Iacovelli, NA; Licitra, L; Nuzzolese, I; Ottini, A; Platini, F; Resteghini, C; Ripamonti, CI; Toffolatti, L, 2023) |
| "Of the 350 LA-HNSCC treated patients, 204 were analyzed." | ( Alfieri, S; Barretta, F; Bergamini, C; Calareso, G; Cavalieri, S; Colombo, E; Cosmai, L; De Feo, G; Di Pede, P; Franceschini, M; Gandelli, M; Guglielmo, M; Iacovelli, NA; Licitra, L; Nuzzolese, I; Ottini, A; Platini, F; Resteghini, C; Ripamonti, CI; Toffolatti, L, 2023) |
| "Advanced head and neck squamous cell carcinoma (HNSCC) patients have been treated with cisplatin (CDDP) chemoradiation, and the variability of treatment effects has been attributed to single nucleotide variants (SNVs) in genes of metabolic pathways." | ( Altemani, JMC; Ferreira, AMC; Lima, CSP; Lourenço, GJ; Macedo, LT, 2023) |
| "Locally advanced head and neck squamous cell carcinomas (HNSCC) are often refractory to platinum-based radiochemotherapy and new immuno-oncological strategies." | ( El Guerzyfy, S; Kaufmann, J; Schmidberger, H; Zahnreich, S, 2023) |
| "Human papilloma virus (HPV) positive head and neck squamous cell carcinoma (HNSCC) tumors respond significantly better to anticancer treatments." | ( Fietkau, R; Frey, B; Gaipl, US; Gehre, S; Gostian, AO; Grottker, F; Hecht, M; Jost, T; Reichardt, CM; Rieckmann, T; Rückert, M; Sengedorj, A, 2023) |
| "Patients had HNSCC that progressed during or after platinum-containing treatment for R/M disease or had recurrence or progression within 3-6 months of previous platinum-containing definitive therapy for locally advanced disease." | ( Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL, 2023) |